论文部分内容阅读
目的:评价CIK细胞免疫治疗晚期消化道肿瘤的临床疗效。方法:选择2010年1月至2014年12月武汉市第五医院肿瘤中心晚期消化系统恶性肿瘤患者。观察组接受CIK细胞免疫治疗,对照组给予姑息减症治疗。比较两组患者总体生存率、无疾病进展生存率,淋巴细胞亚群情况。结果:观察组64例,对照组147例。两组病例年龄、性别、分期、肿瘤部位分布构成无统计学差异。淋巴细胞亚群比较,仅CD3~+两组有统计学差异(P=0.042),观察组和对照组中位无疾病进展生存时间分别为(5±0.8)月、(4±0.4)月,总体中位生存时间分别为(25±7)月、(30±3)月,两组比较,均无统计学差异,P值分别为0.066和0.240。结论:晚期消化系统恶性肿瘤患者,CIK细胞免疫治疗对于改善肿瘤负荷小、生物学特性稍好的晚期消化系统恶性肿瘤的无疾病进展生存可能有一定意义,但总体生存无明显获益。
Objective: To evaluate the clinical efficacy of CIK cell immunotherapy in advanced gastrointestinal tumors. Methods: From January 2010 to December 2014, patients with advanced digestive system malignancy in the Fifth Hospital of Wuhan City were selected. The observation group received CIK cell immunotherapy, while the control group received palliative treatment. The overall survival rate, disease-free survival rate and lymphocyte subsets of two groups were compared. Results: 64 cases in the observation group and 147 cases in the control group. There was no significant difference in the age, sex, stage and tumor location of the two groups. (P = 0.042). The median progression-free survival time in the observation group and the control group were (5 ± 0.8) months, (4 ± 0.4) months, The overall median survival time was (25 ± 7) months, (30 ± 3) months, no significant difference between the two groups, P values were 0.066 and 0.240. CONCLUSIONS: CIK cell immunotherapy in advanced digestive system malignant tumor patients may have some significance in improving disease-free survival of advanced digestive system malignant tumors with small tumor load and slightly better biological characteristics. However, overall survival has no obvious benefit.